Bavarian Nordic A/S

Bavarian Nordic A/S is a leading biotechnology company that specializes in the development, manufacturing, and commercialization of vaccines for infectious diseases and cancer. The company's cutting-edge technology is based on the use of a modified virus called MVA-BN, which acts as a vector to deliver antigens to the immune system. With a diverse portfolio that includes vaccines for smallpox, Ebola, and prostate cancer, among others, Bavarian Nordic is at the forefront of the fight against some of the world's most pressing health challenges. The company is committed to research and development, with a robust pipeline of products in various stages of clinical development. Headquartered in Denmark, Bavarian Nordic has operations in the United States and Germany, and is dedicated to improving global health through innovative solutions.